29.01.2010 • News

Ashland Looks Positively at 2010

Ashland CEO Jim O'Brien told shareholders at its annual meeting that its improved financial results are better than normal seasonality would indicate and that it had exceeded its cost-cutting goals through December. Cost savings on a continuing annual basis hit $405 million by year end, better than its $400 million target, he said.

The company earned $86 million, or $1.10 per share, in the first quarter of its 2010 fiscal year. That compared with a loss of $119 million, or $1.73 per share, in the same period a year earlier.

"If there is a negative on the horizon, it would be raw materials costs," O'Brien said.

Ashland's goal, he said, is to be in a global No. 1 or strong No. 2 position in each of the markets in which it operates.

Company

Logo:

Ashland

500 Hercules Road Building 8145
19808 Wilmington, DE
US

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.